Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Jie Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2658-9525; OpenAlex author ID A5100332904. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 5 papers · 2023: 2 papers

Papers 15

  1. Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41418-023-01188-z↗
  2. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal A… Last author DOI 10.5858/arpa.2021-0471-oa↗
  3. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. Last author DOI 10.1002/cjp2.259↗
  4. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cjp2.260↗
  5. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  6. Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fimmu.2022.1027459↗
  7. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fimmu.2022.942154↗
  8. Development of a four-gene prognostic model for pancreatic cancer based on transcriptome dysregulation. Last author DOI 10.18632/aging.102844↗
  9. Long noncoding RNA TP53TG1 promotes pancreatic ductal adenocarcinoma development by acting as a molecular sponge of microRNA-96. Co-author DOI 10.1111/cas.14136↗
  10. Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1177/1533034618754475↗
  11. Establishment of a non‑coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. Last author DOI 10.3892/ijo.2018.4560↗
  12. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s13277-015-3690-x↗
  13. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Last author DOI 10.1016/j.canlet.2013.12.006↗
  14. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo. Last author DOI 10.1158/1535-7163.mct-12-0650↗
  15. Incidence of pancreatic cancer in chinese patients with chronic pancreatitis. Co-author DOI 10.1159/000322982↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuangni Yu · 11 shared papers, 2013–2023 · strength 1.49
  2. Xianlong Chen · 6 shared papers, 2022–2023 · strength 1.09
  3. Yue Zhang · 3 shared papers, 2022–2023 · strength 0.53
  4. Congwei Jia · 4 shared papers, 2014–2020 · strength 0.35
  5. Cuiping Wang · 3 shared papers, 2015–2018 · strength 0.23
  6. Y. Liu · 1 shared paper, 2023 · strength 0.18
  7. Heng Ma · 1 shared paper, 2023 · strength 0.18
  8. Wei‐Min Tong · 1 shared paper, 2023 · strength 0.18
  9. Yue Zhang · 1 shared paper, 2022 · strength 0.17
  10. Li Zhang · 2 shared papers, 2015–2018 · strength 0.14
  11. Jie Yan · 1 shared paper, 2020 · strength 0.13
  12. Xianbao Zhan · 2 shared papers, 2011–2022 · strength 0.12
  13. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  14. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  15. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  16. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  17. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  18. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  19. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  20. Gang Ren · 1 shared paper, 2022 · strength 0.09
  21. Dan Cao · 1 shared paper, 2022 · strength 0.09
  22. Jian Wang · 1 shared paper, 2022 · strength 0.09
  23. Yongrui Bai · 1 shared paper, 2022 · strength 0.09
  24. Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
  25. Yongwei Sun · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.